Protein Analysis System Targets Bioprocess Efficiency
Nirrin Technologies, announced the commercial launch of TALOS™, a direct protein quantitation system built on the company’s proprietary High-Precision Tunable Laser Spectroscopy (HPTLS™) technology. TALOS™ is designed to simplify protein quantitation across biopharmaceutical workflows by replacing traditional variable pathlength UV workflows with fixed-path near-infrared (NIR) measurement of the peptide backbone. Protein quantitation is possible from 0.1 to 250 mg/mL, in seconds from a 15 µL sample, without dilution, moving optical systems, molecule-specific calibration, or manual pathlength adjustment.
TALOS™ delivers rapid, consistent protein quantitation with the operational simplicity needed for modern bioprocessing workflows, from early process development through GMP manufacturing. With an unprecedented dynamic range, TALOS™ can be used across the full bioprocess workflow as protein concentrations increase from harvest through downstream processing and final release testing. Designed for flexible at-line, in-line, and in situ deployment, TALOS™ is transferable across different unit operations, scales, and manufacturing sites, creating greater consistency and confidence in protein quantitation.
“Protein quantitation is performed throughout biopharmaceutical development and manufacturing, but traditional UV-based workflows introduce operational complexity and have limited deployment options, making it difficult to leverage across operations and scales,” said Bryan Hassell, Ph.D., CEO of Nirrin Technologies. “TALOS™ is designed for the modern biologics manufacturing. The system provides a more reliable and transferable approach to protein quantitation that simplifies operation, reduces workflow burden, and delivers consistent measurements across teams, manufacturing sites, and deployment environments. As biologics manufacturing becomes more distributed, automated, and data-driven, the need for consistent, transferable protein quantitation across workflows and facilities becomes increasingly important.”
How the TALOS™ System is Designed for Manufacturing Workflows
How the TALOS™ System is Designed for Manufacturing Workflows High Concentration Confidence
- Supports protein quantitation from harvest through high-concentration formulation without dilution
Transferability
- Consistent quantitation architecture facilitates method transferability from process development through GMP manufacturing
- Design enables at-line, in-line, and in situ measurements
Operational Simplicity
- Fixed-path measurement architecture designed for reliable, repeatable operation across users and sites
- Targeted NIR measurement of the peptide backbone, reduces dependence on molecule-specific calibration workflows
- Built-in spectral residual and measurement quality metrics to support operational confidence and method monitoring
GMP/Integrated Architecture
- Integrated hardware, software, and analytics simplify deployment and validation
- Audit-ready GMP-aligned, 21 CFR Part 11–capable workflows
Unlike variable pathlength UV systems that rely on moving optical components and slope-based calculations, TALOS™ directly measures molecular vibrations associated with the peptide backbone in the NIR combination-band region through a fixed 1 mm optical pathlength. This fixed-path architecture eliminates mechanical pathlength adjustment while supporting robust, repeatable measurement performance across workflows and deployment configurations.
The at-line configuration of the TALOS™ system is currently available. In-line flow cell and in situ probe configurations are in development and are designed to enable continuous real-time protein monitoring during processing without sampling. All TALOS™ configurations share a common quantitation architecture designed to support consistent measurement performance and method transferability across at-line, in-line, and in situ deployment modes.
This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.